Tiragolumab(Genentech, Inc.)은 Urothelial Carcinoma 표적 항체로, Multiple Myeloma; Non-Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: of anti-TIGIT antibodies as monotherapy or in combination with anti-programmed cell death protein-1 (PD-1) antibody in vivo by gene expression profiling and flow cytometry analyses. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 65.6% (ClinicalTrials.gov NCT04256421). 차별점: novel Fc-enhanced anti-TIGIT antibody, to amplify effector cell activation through FcγR engagement while preserving TIG.
Urothelial Carcinoma
Multiple Myeloma; Non-Hodgkin Lymphoma
Active
ADCC, ADCP, Treg depletion, immune cell activation in human PBM
humanized anti-T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) antibody was recently
novel Fc-enhanced anti-TIGIT antibody, to amplify effector cell activation through FcγR engagement while preserving TIG
of anti-TIGIT antibodies as monotherapy or in combination with anti-programmed cell death protein-1 (PD-1) antibody in vivo by gene expression profiling and flow cytometry analyses with a mouse syngeneic tumor model
ADCC, ADCP, Treg depletion, immune cell activation
PD-L1-positive
resistance mechanisms (e
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Tiragolumab(Genentech, Inc.)은 Urothelial Carcinoma 표적 항체로, Multiple Myeloma; Non-Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: of anti-TIGIT antibodies as monotherapy or in combination with anti-programmed cell death protein-1 (PD-1) antibody in vivo by gene expression profiling and flow cytometry analyses. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 65.6% (ClinicalTrials.gov NCT04256421). 차별점: novel Fc-enhanced anti-TIGIT antibody, to amplify effector cell activation through FcγR engagement while preserving TIG.
Urothelial Carcinoma
Multiple Myeloma; Non-Hodgkin Lymphoma
Active
ADCC, ADCP, Treg depletion, immune cell activation in human PBM
humanized anti-T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) antibody was recently
novel Fc-enhanced anti-TIGIT antibody, to amplify effector cell activation through FcγR engagement while preserving TIG
of anti-TIGIT antibodies as monotherapy or in combination with anti-programmed cell death protein-1 (PD-1) antibody in vivo by gene expression profiling and flow cytometry analyses with a mouse syngeneic tumor model
ADCC, ADCP, Treg depletion, immune cell activation
PD-L1-positive
resistance mechanisms (e
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.